USPTO serial 79300811
HHHBIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 29, 2021
- Examiner
- KETCHUM, BRENDAN J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with HHHBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drugs for medical purposes, namely, drugs for the treatment of oncological and metabolic diseases and disorders; medicines for human purposes, namely, medicine for the treatment of infectious diseases; medicines for human purposes, namely, medicine for the treatment of viral diseases and disorders; medicines for human purposes, namely, medicine for the treatment of respiratory diseases and disorders; therapeutic drugs and agents, namely, therapeutic drugs for the treatment of immune system related diseases and disorders; pharmaceutical preparations for preventing and treating obesity; vaccines; human vaccine preparations; pharmaceutical agents affecting metabolism; protein for medical purposes, namely, protein arrays for diagnosing cancer; protein for medical purposes, namely, protein arrays for diagnosing allergies; peptide for medical purposes, namely, synthetic peptides for the treatment of immune system related diseases and disorders; synthetic protein for the treatment of diabetes; synthetic protein for the treatment of oncological and metabolic diseases and disorders; synthetic peptide for the treatment of obesity; synthetic peptide for the treatment of viral diseases and disorders; pharmaceutical preparations containing peptides as the active ingredients, namely, pharmaceutical preparations for the treatment of neurological diseases and disorders | ACTIVE | — |
| 042 | Research relating to pharmaceuticals, namely, pharmaceutical research services; medicine research, namely, research and development of medicines; medical analysis services of peptide for the treatment of people; research for medical products, namely medical research; chemical research; biological research; laboratory research in the field of pharmaceuticals; clinical studies of medicines, namely, conducting clinical trials for others; operation of medical laboratory, namely, medical laboratory services; scientific research for medical purposes; research and development of peptide for medical purposes; research of biology; research and development of peptide for scientific or laboratory purposes; drug discovery services; research and development of technology for biotechnology; development of pharmaceutical preparations and medicines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 29, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 28, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 23, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 28, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 28, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 29, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 29, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 13, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 13, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 13, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 24, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 24, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 24, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 11, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 10, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 5, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 5, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 20, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 19, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 16, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 12, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 11, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Dec 24, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |